tei Solutions, Mears Technologies and K2 Energy Collaborate for Improved Efficiency of Solar Cells
TSUKUBA, JAPAN, December 20, 2010 — tei Solutions, an integrated foundry providing 100mm and 300mm R&D services, announces a collaboration with Mears Technologies, a US-based emerging materials technology company, to explore the use of the Mears Silicon Technology (MST) in the development and production of solar cells. Mears will utilize tei’s 100mm Super Clean Fab to produce cells for testing in January 2011. Read more ...

2G Development Milestone Ink Jet Processing and Continuous Wire Processing
Zenergy Power (AIM:ZEN.L), the superconductor energy technology company, is pleased to announce that it has successfully completed the development of the high-speed ink jet printing processes necessary for the low-cost production of its Second Generation ('2G') superconducting wire. Combined with the recent qualifi cation of Honeywell Speciality Materials as an industrial supplier to the Group, this achievement brings Zenergy Power to the end of the research and development of its 2G wire processes and enables it to commence industrial scaling of production once the qualifi cation of industrial supply of metal tapes from ThyssenKrupp VDM GmbH ('ThyssenKrupp') has been completed. The Group's work with ThyssenKrupp was recently boosted by support of the German government through a funded project and it is anticipated that qualifi cation will occur in the second half of this year. Read more ...

AgaMatrix and sanofi-aventis Enter Global Diabetes Partnership
Salem, New Hampshire, March 31, 2010 – AgaMatrix, Inc. and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) today announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring (BGM) solutions. Under the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop innovative solutions in diabetes management that incorporate AgaMatrix's WaveSense™ technology. Sanofi-aventis will commercialize through its Global Diabetes Division such integrated solutions for patients with diabetes, along with current sanofi-aventis insulins and delivery devices. Sanofi-aventis' insulin and device portfolio include Lantus®, a basal insulin that is the number one insulin prescribed worldwide, and Apidra®, a leading fast-acting insulin, plus its easy-to-use delivery pens SoloSTAR® and ClikSTAR®. Read more ...

Strengthening of Collaboration with ThyssenKrupp through New Project for Second Generation ('2G') wire
Zenergy Power (AIM:ZEN.L), the superconductor energy technology company, is pleased to announce a new funded project to support its work with ThyssenKrupp VDM GmbH ('ThyssenKrupp VDM') on advanced research activities relating to the Group's development of mass production techniques for low-cost 2G superconductor wire. The funding supports a €1.5m project (named 'SupraMetall') with a grant contribution from the regional government of North Rhine-Westfalia's Ministry of Economics and Energy of €860,000. Read more ...

Institutional Placing to Raise £20,040,000
Zenergy Power (AIM:ZEN.L), the superconductor energy technology company, is pleased to announce that the Group has successfully raised £20,040,000 (approximately £19,200,000 net of expenses) by way of a placing of 16,700,000 new ordinary shares of 1p each ('Ordinary Shares') in the Company ('Placing Shares') at a price of 120p per Placing Share with a number of new and existing institutional investors (the 'Placing'). Read more ...

First Commercial Sale of Fault Current Limiter
Zenergy Power (AIM:ZEN.L), the superconductor energy technology company, is pleased to announce the receipt of the fi rst commercial order for a superconductor Fault Current Limiter ('FCL'). Placed by UK-based Applied Superconductor Limited ('Applied Superconductor'), the landmark order is for the purchase of a medium-voltage unit that is scheduled for installation into the distribution network of CE Electric UK in the second half of this year. Read more ...